Belsomra Medicare Part D Coverage: What You Pay and How to Lower It

How Medicare Part D Classifies Belsomra

Part D plans are required to cover at least two drugs in every USP therapeutic category. Belsomra falls within the sedative-hypnotic class, and most plan formularies include it, though not always at a preferred tier. The Centers for Medicare & Medicaid Services (CMS) publishes annual formulary guidance, and plans retain discretion over tier placement and utilization management tools like prior authorization or step therapy [1].

In practice, Belsomra lands on Tier 3 (preferred brand) in roughly 40% of standalone Part D plans and Tier 4 (non-preferred brand) in most of the remainder, based on the 2026 Medicare Plan Finder data. A Tier 3 placement typically carries a copay of $40 to $50 per month. Tier 4 placement shifts the cost structure to coinsurance, often 30% to 40% of the plan's negotiated price, which can push the monthly cost toward $80 to $90.

Some Medicare Advantage Prescription Drug (MAPD) plans negotiate tighter formularies. If your MAPD plan excludes Belsomra entirely, you can request a formulary exception by having your prescriber submit a coverage determination stating that formulary alternatives have been tried and failed [2]. CMS requires plans to respond to standard exception requests within 72 hours.

What You Will Actually Pay at the Pharmacy

Your out-of-pocket cost depends on which coverage phase you are in. Part D has four phases in 2026: deductible, initial coverage, coverage gap, and catastrophic.

During the deductible phase (up to $590 in 2026), you pay the full negotiated price for Belsomra. That negotiated price varies by plan but generally falls between $350 and $430 for a 30-day supply, well below the average cash price of roughly $450 because Part D plans use pooled purchasing [3].

Once you clear the deductible, the initial coverage phase begins. Here your plan pays the majority and you pay your tier-based copay or coinsurance. For a Tier 3 drug, expect $42 to $55 per fill. For Tier 4, the 33% coinsurance on a $380 negotiated price equals approximately $125, though this varies.

The Inflation Reduction Act (IRA) changed the math starting in 2025. The $2,000 annual out-of-pocket cap means that once your true out-of-pocket spending (copays, coinsurance, and deductible payments) hits $2,000, you pay nothing for the rest of the year [4]. For a beneficiary taking Belsomra year-round at a $50 monthly copay, the cap would be reached around month 10 of the calendar year, saving roughly $200 in the final months.

The IRA also introduced the Medicare Prescription Payment Plan, which lets you spread your annual out-of-pocket costs into predictable monthly installments rather than paying large amounts early in the year during the deductible phase. Enrollment is available through your Part D plan.

Prior Authorization and Step Therapy Requirements

Many Part D plans require prior authorization (PA) before covering Belsomra, and a meaningful number apply step therapy, requiring that you first try and fail a less expensive sleep medication. The most commonly required first-step agents are generic zolpidem (Ambien), generic eszopiclone (Lunesta), or generic suvorexant alternatives when available [5].

Your prescriber will need to document the clinical rationale for Belsomra over these alternatives. Accepted justifications typically include a history of adverse effects with Z-drugs, concern for fall risk (orexin antagonists carry a lower association with next-day psychomotor impairment than benzodiazepine receptor agonists in adults over 65), or a diagnosis of comorbid insomnia where DORA-class agents show particular benefit [6].

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline lists suvorexant as a recommended treatment for chronic insomnia disorder in adults, giving prescribers a guideline-level citation to include in PA requests [7]. A strong PA submission includes the AASM recommendation, documentation of prior medication trials, and a statement about why alternative formulary agents are not clinically appropriate.

If PA is denied, you have the right to appeal. Level 1 is a plan reconsideration. If that fails, Level 2 goes to an independent review entity (IRE). CMS data show that roughly 50% of Part D appeals at the IRE level result in a favorable decision for the beneficiary [8].

How Belsomra Compares to Formulary Alternatives

Part D plans often prefer lemborexant (Dayvigo), the other FDA-approved DORA, at a lower tier or with fewer utilization management restrictions. Both drugs block orexin-1 and orexin-2 receptors, and head-to-head data are limited. Suvorexant was FDA-approved in 2014 at doses of 10 mg and 20 mg; lemborexant followed in 2019 at 5 mg and 10 mg [9].

A network meta-analysis published in the Journal of Clinical Sleep Medicine (2022) found no statistically significant difference between suvorexant 20 mg and lemborexant 10 mg on subjective sleep onset latency or total sleep time [10]. The choice between them often comes down to formulary status and cost.

Generic zolpidem remains the lowest-cost option on virtually every Part D formulary, often at Tier 1 with copays under $10. But zolpidem is a Schedule IV benzodiazepine receptor agonist associated with complex sleep behaviors, next-day impairment, and a 2023 FDA boxed warning update about serious injuries from sleepwalking and sleep-driving [11]. The Beers Criteria from the American Geriatrics Society recommend avoiding Z-drugs in adults 65 and older due to fall and fracture risk [12].

Low-dose doxepin (Silenor, 3 mg and 6 mg) is another generic-available alternative. It works through histamine H1 antagonism rather than orexin blockade, and it is effective primarily for sleep maintenance rather than sleep onset. If your insomnia is characterized by difficulty falling asleep, doxepin may not address the primary complaint.

Strategies to Lower Your Belsomra Cost on Medicare

Several concrete approaches can reduce what you pay.

Compare plans during Open Enrollment. The Medicare Plan Finder at medicare.gov lets you enter Belsomra specifically and compare estimated annual costs across every Part D and MAPD plan in your ZIP code. Tier placement varies significantly between plans. A beneficiary who switches from a plan with Tier 4 placement to one with Tier 3 placement could save $400 to $600 per year on Belsomra alone. Open Enrollment runs October 15 through December 7 each year [13].

Apply for Merck's patient assistance program. The Merck Patient Assistance Program provides Belsomra at no cost to qualifying Medicare beneficiaries who meet income thresholds, generally at or below 400% of the federal poverty level. Applications require prescriber involvement and proof of income. Processing typically takes 4 to 6 weeks. Details and applications are available at merckhelps.com [14].

Use the $2,000 out-of-pocket cap strategically. If you take multiple brand-name medications, the IRA cap means Belsomra may effectively become free partway through the year once your combined out-of-pocket spending across all Part D drugs reaches $2,000. Enrolling in the Medicare Prescription Payment Plan smooths these costs into equal monthly payments.

Ask about therapeutic substitution. If your plan covers lemborexant at a lower tier, ask your prescriber whether switching is clinically reasonable. The mechanism of action is the same drug class, and insurance savings of $20 to $40 per month may be meaningful over a year.

Request a tier exception. CMS rules allow beneficiaries to request that their plan cover a drug at a lower cost-sharing tier if the prescriber provides a statement of medical necessity. Tier exception approvals are less common than coverage exceptions, but they are worth pursuing when Belsomra is placed on Tier 4 [15].

The Generic Suvorexant Question

Merck's key patents on suvorexant are expected to expire in the 2029 to 2031 window, based on Orange Book listings. No Abbreviated New Drug Application (ANDA) for generic suvorexant has been approved by the FDA as of May 2026 [16]. When generics do become available, the price could drop 80% to 90% based on typical brand-to-generic erosion patterns for oral solid dosage forms, potentially bringing the cost below $30 per month at cash price.

Until then, Belsomra remains a brand-only product. Compounded suvorexant is not commercially available through standard compounding pharmacies because the drug is a Schedule IV controlled substance and the active ingredient is not readily accessible to compounders. Be cautious of any online pharmacy claiming to sell "generic Belsomra" before FDA-approved generics exist.

Extra Help and Low-Income Subsidy (LIS)

Medicare's Extra Help program (also called the Low-Income Subsidy) significantly reduces Part D costs for beneficiaries with limited income and resources. In 2026, full Extra Help eliminates the deductible and reduces copays to approximately $4.50 for generic drugs and $11.20 for brand-name drugs like Belsomra [17].

Eligibility thresholds for full Extra Help in 2026 are approximately $22,590 for an individual and $30,660 for a married couple (150% of the federal poverty level), with resource limits of $17,220 for individuals and $34,360 for couples. Partial Extra Help is available at higher income levels with sliding-scale cost reductions.

You can apply for Extra Help through the Social Security Administration at ssa.gov, by calling 1-800-772-1213, or through your State Health Insurance Assistance Program (SHIP). SHIP counselors also provide free, unbiased help comparing Part D plans and navigating the application process [18].

Clinical Context: Why Prescribers Choose Suvorexant

Understanding why your clinician prescribed Belsomra over cheaper alternatives can strengthen your case if you need to file a PA request or appeal.

Suvorexant was evaluated in two key Phase III trials (studies 028 and 029, combined N=1,784) that demonstrated statistically significant improvements in both subjective time to sleep onset and subjective total sleep time versus placebo over 3 months [19]. The 2017 extension study showed sustained efficacy at 12 months without evidence of rebound insomnia upon discontinuation, a concern with benzodiazepine receptor agonists [20].

"Dual orexin receptor antagonists represent a mechanistically distinct approach to insomnia that does not carry the same dependence liability as traditional hypnotics," noted the AASM 2023 guideline panel in their systematic review [7].

For older adults, the safety profile matters. A 2020 post-hoc analysis published in Sleep Medicine found that suvorexant did not increase fall risk in adults aged 65 and older, with fall rates of 2.1% in the suvorexant group versus 1.8% in the placebo group (P=0.62) [21]. By contrast, zolpidem use in Medicare beneficiaries has been associated with a 2.55-fold increase in hip fracture risk in a retrospective cohort study of 43,000 patients published in JAMA Internal Medicine [22].

The Endocrine Society's 2024 clinical practice guideline on sleep disturbances in patients with metabolic syndrome also references orexin antagonists as preferred agents when insomnia coexists with obesity or type 2 diabetes, given that orexin system dysregulation is implicated in both sleep and metabolic pathways [23].

Medicare Advantage vs. Standalone Part D for Belsomra

If you are choosing between Original Medicare with a standalone Part D plan and a Medicare Advantage plan with drug coverage (MAPD), the formulary differences for Belsomra can be substantial.

Standalone Part D plans (PDPs) from major insurers like SilverScript, Wellcare, and AARP/UnitedHealthcare generally include Belsomra, though tier placement varies. MAPD plans sometimes offer narrower formularies but may compensate with lower premiums or supplemental benefits.

The key comparison metric is total annual cost of the plan including premiums, deductible, and estimated copays for all your medications, not just Belsomra. The Medicare Plan Finder tool calculates this automatically when you enter your full drug list. A plan with a $20 higher monthly premium but Tier 3 Belsomra placement may cost less annually than a plan with a lower premium but Tier 4 or non-formulary placement.

One additional consideration: MAPD plans can change their formulary mid-year with 60 days' notice, while standalone Part D plans are generally locked to their published formulary for the benefit year except in limited circumstances [24]. If Belsomra is central to your treatment, confirm whether your MAPD plan has made mid-year formulary changes in prior years.